A Phase III, randomized, open-label, comparator-controlled, parallel-group, multicenter study to compare the effects of exenatide and insulin glargine on beta-cell function and cardiovascular risk markers in subjects with type 2 diabetes treated with metformin who have not achieved target HbA1c

Authors
Category Primary study
Registry of TrialsISRCTN registry
Year 2005
This article has no abstract
Epistemonikos ID: a5ae4c59f8168186fa7e11405c661a4846811153
First added on: Jan 18, 2025